Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IlluminaXSWX:ILMN 76 3-Year Book Growth Rate is -24.70% as of Jun. 2026. GuruFocus rates XSWX:ILMN with a GF Score™ of 76/100 and a GF Value™ of CHF107.32. The stock has 7 warning signs investors should review. Among 192 Medical Diagnostics & Research companies, Illumina ranks worse than 80.73% on this metric.
During the past 12 months, Illumina's average Book Value per Share Growth Rate was 28.20% per year.
During the past 3 years, the average Book Value per Share Growth Rate was -24.70% per year.
During the past 5 years, the average Book Value per Share Growth Rate was -19.70% per year.
During the past 10 years, the average Book Value per Share Growth Rate was 5.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Illumina was 95.90% per year. The lowest was -39.80% per year. And the median was 10.10% per year.
Illumina (XSWX:ILMN) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Illumina 3-Year Book Growth Rate Related Terms
XSWX:ILMN vs MTD, DGX, LH: 3-Year Book Growth Rate Comparison
For the Diagnostics & Research subindustry, Illumina's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Illumina 3-Year Book Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Illumina's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Illumina's 3-Year Book Growth Rate falls into.
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of -24.70% mean?
Illumina (XSWX:ILMN) has a 3-Year Book Growth Rate of -24.70% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Illumina and its competitors. According to the industry distribution chart, Illumina ranks #155 out of 192 companies in the Medical Diagnostics & Research industry, placing it in the top 80.7%.
Is Illumina's 3-Year Book Growth Rate too high?
Illumina's current 3-Year Book Growth Rate is -24.70%. Based on the distribution chart, Illumina ranks #155 out of 192 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Illumina has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Illumina's 3-Year Book Growth Rate compare to MTD and DGX?
According to the Medical Diagnostics & Research industry distribution chart, Illumina ranks #155 out of 192 companies for 3-Year Book Growth Rate. This places Illumina in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Medical Diagnostics & Research company?
A good 3-Year Book Growth Rate depends on the Medical Diagnostics & Research industry context. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Illumina and its competitors. Illumina's current 3-Year Book Growth Rate is -24.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Illumina stock overvalued right now?
Illumina (XSWX:ILMN) has a current 3-Year Book Growth Rate of -24.70%. The stock's GF Value™ is CHF107.32, compared to a current price of CHF155.14 — trading 44.6% above its estimated fair value. The current 3-Year Book Growth Rate is -24.70%. Illumina's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Illumina (XSWX:ILMN), the current 3-Year Book Growth Rate is -24.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Illumina (XSWX:ILMN) Overvalued in 2026?
Based on GuruFocus' analysis, Illumina stock appears to be overvalued.
The current stock price of CHF155.14 is trading 44.6% above its estimated GF Value™ of CHF107.32.
Key valuation signals for XSWX:ILMN:
3-Year Book Growth Rate: -24.70%
GF Value™: CHF107.32 vs. price of CHF155.14 (44.6% above fair value)
No single metric tells the full story. See the XSWX:ILMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
76GF Score
Get the complete analysis for XSWX:ILMN
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ILMN has been successfully added to your 
